The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients

Marilyn Hammer, Corey Casper, Ted A. Gooley, Paul V. O'Donnell, Michael Boeckh, Irl B. Hirsch

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic cell transplantation (HCT) continues to be associated with substantial rates of nonrelapse mortality (NRM). Numerous factors influence glucose metabolism among HCT recipients. We hypothesized that "malglycemia," defined as hyperglycemia, hypoglycemia or increased glycemic variability, is associated with increased mortality in HCT patients. In a retrospective cohort study Cox regression was used to assess the association of malglycemia after transplant with day 200 NRM. A total of 66,062 blood glucose (BG) measurements from 1175 adult allogeneic HCT recipients between 2000 and 2005 at the Fred Hutchinson Cancer Research Center were evaluated (median 0.55 values per patient-day, range: 0.09-3.62). Overall, there were 215 cases of NRM by day 200 post-HCT and 601 deaths from any cause throughout observation. After adjustment for previously identified factors associated with NRM, all 3 components of malglycemia were associated with increased NRM when individually modeled as time-dependent covariates. Specifically, the hazard ratio for death was 1.93 for BG >200 mg/dL (P = .0009) and 2.78 for BG >300 (P = .0004) compared with BG 101-150 mg/dL. A minimum BG ≤89 was associated with a risk of day 200 NRM 2.17 times that of a minimum BG >89 (P < .0001). The upper quartile of glucose variability was associated with a 14.57-fold increase in risk of NRM by day 200 relative to the first quartile (P < .0001). These retrospective data indicate that malglycemia is associated with mortality following HCT. The applicability of these findings to other situations and whether correcting malglycemia in HCT can lead to reductions in mortality remain to be determined.

Original languageEnglish (US)
Pages (from-to)344-351
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Cell Transplantation
Transplants
Mortality
Blood Glucose
Transplant Recipients
Glucose
Hypoglycemia
Hyperglycemia
Cause of Death
Cohort Studies
Retrospective Studies
Observation
Research
Neoplasms

Keywords

  • Glycemic variability
  • Hematopoietic cell transplant
  • Hyperglycemia
  • Hypoglycemia
  • Infection
  • Mortality

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients. / Hammer, Marilyn; Casper, Corey; Gooley, Ted A.; O'Donnell, Paul V.; Boeckh, Michael; Hirsch, Irl B.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 3, 03.2009, p. 344-351.

Research output: Contribution to journalArticle

Hammer, Marilyn ; Casper, Corey ; Gooley, Ted A. ; O'Donnell, Paul V. ; Boeckh, Michael ; Hirsch, Irl B. / The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 3. pp. 344-351.
@article{1749cce5452047bb9bc03463f7400c40,
title = "The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients",
abstract = "Allogeneic hematopoietic cell transplantation (HCT) continues to be associated with substantial rates of nonrelapse mortality (NRM). Numerous factors influence glucose metabolism among HCT recipients. We hypothesized that {"}malglycemia,{"} defined as hyperglycemia, hypoglycemia or increased glycemic variability, is associated with increased mortality in HCT patients. In a retrospective cohort study Cox regression was used to assess the association of malglycemia after transplant with day 200 NRM. A total of 66,062 blood glucose (BG) measurements from 1175 adult allogeneic HCT recipients between 2000 and 2005 at the Fred Hutchinson Cancer Research Center were evaluated (median 0.55 values per patient-day, range: 0.09-3.62). Overall, there were 215 cases of NRM by day 200 post-HCT and 601 deaths from any cause throughout observation. After adjustment for previously identified factors associated with NRM, all 3 components of malglycemia were associated with increased NRM when individually modeled as time-dependent covariates. Specifically, the hazard ratio for death was 1.93 for BG >200 mg/dL (P = .0009) and 2.78 for BG >300 (P = .0004) compared with BG 101-150 mg/dL. A minimum BG ≤89 was associated with a risk of day 200 NRM 2.17 times that of a minimum BG >89 (P < .0001). The upper quartile of glucose variability was associated with a 14.57-fold increase in risk of NRM by day 200 relative to the first quartile (P < .0001). These retrospective data indicate that malglycemia is associated with mortality following HCT. The applicability of these findings to other situations and whether correcting malglycemia in HCT can lead to reductions in mortality remain to be determined.",
keywords = "Glycemic variability, Hematopoietic cell transplant, Hyperglycemia, Hypoglycemia, Infection, Mortality",
author = "Marilyn Hammer and Corey Casper and Gooley, {Ted A.} and O'Donnell, {Paul V.} and Michael Boeckh and Hirsch, {Irl B.}",
year = "2009",
month = "3",
doi = "10.1016/j.bbmt.2008.12.488",
language = "English (US)",
volume = "15",
pages = "344--351",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients

AU - Hammer, Marilyn

AU - Casper, Corey

AU - Gooley, Ted A.

AU - O'Donnell, Paul V.

AU - Boeckh, Michael

AU - Hirsch, Irl B.

PY - 2009/3

Y1 - 2009/3

N2 - Allogeneic hematopoietic cell transplantation (HCT) continues to be associated with substantial rates of nonrelapse mortality (NRM). Numerous factors influence glucose metabolism among HCT recipients. We hypothesized that "malglycemia," defined as hyperglycemia, hypoglycemia or increased glycemic variability, is associated with increased mortality in HCT patients. In a retrospective cohort study Cox regression was used to assess the association of malglycemia after transplant with day 200 NRM. A total of 66,062 blood glucose (BG) measurements from 1175 adult allogeneic HCT recipients between 2000 and 2005 at the Fred Hutchinson Cancer Research Center were evaluated (median 0.55 values per patient-day, range: 0.09-3.62). Overall, there were 215 cases of NRM by day 200 post-HCT and 601 deaths from any cause throughout observation. After adjustment for previously identified factors associated with NRM, all 3 components of malglycemia were associated with increased NRM when individually modeled as time-dependent covariates. Specifically, the hazard ratio for death was 1.93 for BG >200 mg/dL (P = .0009) and 2.78 for BG >300 (P = .0004) compared with BG 101-150 mg/dL. A minimum BG ≤89 was associated with a risk of day 200 NRM 2.17 times that of a minimum BG >89 (P < .0001). The upper quartile of glucose variability was associated with a 14.57-fold increase in risk of NRM by day 200 relative to the first quartile (P < .0001). These retrospective data indicate that malglycemia is associated with mortality following HCT. The applicability of these findings to other situations and whether correcting malglycemia in HCT can lead to reductions in mortality remain to be determined.

AB - Allogeneic hematopoietic cell transplantation (HCT) continues to be associated with substantial rates of nonrelapse mortality (NRM). Numerous factors influence glucose metabolism among HCT recipients. We hypothesized that "malglycemia," defined as hyperglycemia, hypoglycemia or increased glycemic variability, is associated with increased mortality in HCT patients. In a retrospective cohort study Cox regression was used to assess the association of malglycemia after transplant with day 200 NRM. A total of 66,062 blood glucose (BG) measurements from 1175 adult allogeneic HCT recipients between 2000 and 2005 at the Fred Hutchinson Cancer Research Center were evaluated (median 0.55 values per patient-day, range: 0.09-3.62). Overall, there were 215 cases of NRM by day 200 post-HCT and 601 deaths from any cause throughout observation. After adjustment for previously identified factors associated with NRM, all 3 components of malglycemia were associated with increased NRM when individually modeled as time-dependent covariates. Specifically, the hazard ratio for death was 1.93 for BG >200 mg/dL (P = .0009) and 2.78 for BG >300 (P = .0004) compared with BG 101-150 mg/dL. A minimum BG ≤89 was associated with a risk of day 200 NRM 2.17 times that of a minimum BG >89 (P < .0001). The upper quartile of glucose variability was associated with a 14.57-fold increase in risk of NRM by day 200 relative to the first quartile (P < .0001). These retrospective data indicate that malglycemia is associated with mortality following HCT. The applicability of these findings to other situations and whether correcting malglycemia in HCT can lead to reductions in mortality remain to be determined.

KW - Glycemic variability

KW - Hematopoietic cell transplant

KW - Hyperglycemia

KW - Hypoglycemia

KW - Infection

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=59449090412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449090412&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.12.488

DO - 10.1016/j.bbmt.2008.12.488

M3 - Article

C2 - 19203725

AN - SCOPUS:59449090412

VL - 15

SP - 344

EP - 351

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -